559 related articles for article (PubMed ID: 22108301)
21. Effects of denosumab on bone mineral density and bone turnover in postmenopausal women.
Bone HG; Bolognese MA; Yuen CK; Kendler DL; Wang H; Liu Y; San Martin J
J Clin Endocrinol Metab; 2008 Jun; 93(6):2149-57. PubMed ID: 18381571
[TBL] [Abstract][Full Text] [Related]
22. Denosumab: a review of its use in the treatment of postmenopausal osteoporosis.
Moen MD; Keam SJ
Drugs Aging; 2011 Jan; 28(1):63-82. PubMed ID: 21174488
[TBL] [Abstract][Full Text] [Related]
23. Spotlight on denosumab in postmenopausal osteoporosis.
Moen MD; Keam SJ
BioDrugs; 2011 Aug; 25(4):261-4. PubMed ID: 21815702
[TBL] [Abstract][Full Text] [Related]
24. How to manage postmenopausal osteoporosis?
Body JJ
Acta Clin Belg; 2011; 66(6):443-7. PubMed ID: 22338309
[TBL] [Abstract][Full Text] [Related]
25. Ranking antireabsorptive agents to prevent vertebral fractures in postmenopausal osteoporosis by mixed treatment comparison meta-analysis.
Migliore A; Broccoli S; Massafra U; Cassol M; Frediani B
Eur Rev Med Pharmacol Sci; 2013 Mar; 17(5):658-67. PubMed ID: 23543450
[TBL] [Abstract][Full Text] [Related]
26. Cost-effectiveness of denosumab in the treatment of postmenopausal osteoporosis in Canada.
Chau D; Becker DL; Coombes ME; Ioannidis G; Adachi JD; Goeree R
J Med Econ; 2012; 15 Suppl 1():3-14. PubMed ID: 23035625
[TBL] [Abstract][Full Text] [Related]
27. Effects of denosumab on bone mineral density and bone turnover in postmenopausal women transitioning from alendronate therapy.
Kendler DL; Roux C; Benhamou CL; Brown JP; Lillestol M; Siddhanti S; Man HS; San Martin J; Bone HG
J Bone Miner Res; 2010 Jan; 25(1):72-81. PubMed ID: 19594293
[TBL] [Abstract][Full Text] [Related]
28. Denosumab for postmenopausal osteoporosis?
Drug Ther Bull; 2012 Jan; 50(1):6-8. PubMed ID: 22241889
[TBL] [Abstract][Full Text] [Related]
29. [Denosumab for treatment of postmenopausal osteoporosis].
Syversen U; Halse JI; Geisler J; Eriksen EF
Tidsskr Nor Laegeforen; 2011 Oct; 131(19):1893-6. PubMed ID: 21984295
[TBL] [Abstract][Full Text] [Related]
30. A new antiresorptive approach to the treatment of fragility fractures: long-term efficacy and safety of denosumab.
Tarantino U; Celi M; Feola M; Liuni FM; Resmini G; Iolascon G
Aging Clin Exp Res; 2013 Oct; 25 Suppl 1():S65-9. PubMed ID: 24046047
[TBL] [Abstract][Full Text] [Related]
31. Sclerostin and DKK1 in postmenopausal osteoporosis treated with denosumab.
Gatti D; Viapiana O; Fracassi E; Idolazzi L; Dartizio C; Povino MR; Adami S; Rossini M
J Bone Miner Res; 2012 Nov; 27(11):2259-63. PubMed ID: 22692843
[TBL] [Abstract][Full Text] [Related]
32. [Osteoporosis treatment by anti-RANKL antibody].
Sugimoto T
Clin Calcium; 2011 Aug; 21(8):1209-15. PubMed ID: 21814027
[TBL] [Abstract][Full Text] [Related]
33. Denosumab and bisphosphonates: different mechanisms of action and effects.
Baron R; Ferrari S; Russell RG
Bone; 2011 Apr; 48(4):677-92. PubMed ID: 21145999
[TBL] [Abstract][Full Text] [Related]
34. [The role of rank-ligand inhibition in the treatment of postmenopausal osteoporosis].
Varenna M; Gatti D
Reumatismo; 2010; 62(3):163-71. PubMed ID: 21052563
[TBL] [Abstract][Full Text] [Related]
35. Comparison of the effect of denosumab and alendronate on BMD and biochemical markers of bone turnover in postmenopausal women with low bone mass: a randomized, blinded, phase 3 trial.
Brown JP; Prince RL; Deal C; Recker RR; Kiel DP; de Gregorio LH; Hadji P; Hofbauer LC; Alvaro-Gracia JM; Wang H; Austin M; Wagman RB; Newmark R; Libanati C; San Martin J; Bone HG
J Bone Miner Res; 2009 Jan; 24(1):153-61. PubMed ID: 18767928
[TBL] [Abstract][Full Text] [Related]
36. [Present and future of the treatment of osteoporosis with monoclonal antibodies].
Fiter Aresté J
Reumatol Clin; 2011 Sep; 7 Suppl 2():S8-12. PubMed ID: 21924213
[TBL] [Abstract][Full Text] [Related]
37. Denosumab for the prevention of osteoporotic fractures in postmenopausal women.
Waugh N; Royle P; Scotland G; Henderson R; Hollick R; McNamee P
Health Technol Assess; 2011 May; 15 Suppl 1():51-9. PubMed ID: 21609653
[TBL] [Abstract][Full Text] [Related]
38. Denosumab: recent update in postmenopausal osteoporosis.
Silva I; Branco JC
Acta Reumatol Port; 2012; 37(4):302-13. PubMed ID: 24126422
[TBL] [Abstract][Full Text] [Related]
39. Efficacy and safety of denosumab in postmenopausal women with osteopenia or osteoporosis: a systematic review and a meta-analysis.
Anastasilakis AD; Toulis KA; Goulis DG; Polyzos SA; Delaroudis S; Giomisi A; Terpos E
Horm Metab Res; 2009 Oct; 41(10):721-9. PubMed ID: 19536731
[TBL] [Abstract][Full Text] [Related]
40. Treatment with denosumab reduces the incidence of new vertebral and hip fractures in postmenopausal women at high risk.
Boonen S; Adachi JD; Man Z; Cummings SR; Lippuner K; Törring O; Gallagher JC; Farrerons J; Wang A; Franchimont N; San Martin J; Grauer A; McClung M
J Clin Endocrinol Metab; 2011 Jun; 96(6):1727-36. PubMed ID: 21411557
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]